



## CLINICAL TRIALS

### BREAST CANCER

Breast Cancer Index (BCI) Registry Study.

MammaPrint, Blueprint, and Full-Genome Data Linked with Clinical Data to Evaluate New Gene Expression Profiles: An Adaptable Registry (FLEX Registry)

A Randomized Phase 3 study of Abemaciclib plus Standard Adjuvant Endocrine Therapy in Participants with High-Risk, Node-Positive, HR+, HER 2+ Breast Cancer who have completed Adjuvant HER2 Targeted Therapy.

A Randomized Phase 3 study of SAR439859 Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients with ER(+), HER2(-) Breast Cancer who have not Received any Prior Systemic Anti-Cancer Treatment for Advanced Disease.

### COLON CANCER

A randomized Phase 3 trial to Compare the Efficacy and Safety of Fruquintinib Plus best Supportive Care to Placebo Plus best Supportive Care in Patients with Refractory Metastatic Colorectal Cancer.

### BLADDER CANCER

A phase 3 randomized study of Atezolizumab versus placebo as adjuvant therapy in patients with High Risk Muscle Invasive Bladder Cancer who are CTDNA-Positive following cystectomy.

### NON-SMALL CELL LUNG CANCER

#### METASTATIC NON-SMALL LUNG CANCER

A Randomized Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Atezolizumab given in Combination with Cabozantinib Versus Docetaxel Monotherapy in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with an AntiPDL1/PD-1 Antibody and Platinum-Containing 1 Antibody and Platinum-Containing Chemotherapy.

#### METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

A phase 2 study to evaluate the efficacy of Dostarlimab plus chemotherapy Versus Pembrolizumab plus chemotherapy in Metastatic Non-Squamous Non-Small Cell Lung Cancer



CANCER CARE CENTERS  
OF BREVARD



The US Oncology  
Network

### **STAGE III NON-SMALL CELL LUNG CANCER**

A Phase 3 Randomized Study of Atezolizumab Compared with Durvalumab in Patients with Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum Based Chemoradiation.

### **FIRST LINE NON-SMALL CELL LUNG CANCER**

A randomized Trial of Tomivosertib in Combination with Anti-PD-(L)1 Therapy in Subjects with Non-Small Cell Lung Cancer as First Line Therapy or When Progressing on Single Agent First Line Anti-PD-(L)1 Therapy.

### **ON HOLD**

Metastatic Non-Squamous, Non-Small Cell Lung Cancer

A Study Evaluating the Safety, Tolerability, and Efficacy of AMG510 Alone or in Combination with Pembrolizumab, With or Without Chemotherapy, in Subjects with Metastatic Non-Squamous, Non-Small Cell Lung Cancer with KRASp.12C Mutation.

### **OTHER TRIALS MAY BE AVAILABLE, PLEASE CALL TO INQUIRE:**

Deborah Schmitt, RN OCN

Clinical Research Nurse

Cancer Care Center of Brevard

321-405-1022

Deborah.Schmitt@usoncology.com

[www.cancercarebrevard.com](http://www.cancercarebrevard.com)